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Market access and pricing of pharmaceuticals are increasingly contingent on the ability to 
demonstrate comparative effectiveness and cost-effectiveness. As such, it is widely recognised that 
predictions of the economic potential of drug candidates in development could inform decisions 
across the product lifecycle. This may be challenging when safety and efficacy profiles in terms of the 
relevant clinical outcomes are unknown or highly uncertain early in product development. Linking 
pharmacometrics and pharmacoeconomics, such that outputs from pharmacometric models serve as 
inputs to pharmacoeconomic models, may provide a framework for extrapolating from early phase 
studies to predict economic outcomes and characterise decision uncertainty. This article reviews the 
published studies that have implemented this methodology and used simulation to either inform drug 
development decisions and/or optimise the use of drug treatments. Some of the key practical issues 
involved in linking pharmacometrics and pharmacoeconomics, including the choice of final outcome 
measures, methods of incorporating evidence on comparator treatments, approaches to handling 
multiple intermediate endpoints, approaches to quantifying uncertainty, and issues of model 
validation, are also discussed. Finally, we have considered the potential barriers that may have limited 
the adoption of this methodology and suggest that closer alignment between the disciplines of clinical 
pharmacology, pharmacometrics, and pharmacoeconomics, may help to realise the potential benefits 








Many jurisdictions across OECD countries require evidence of cost-effectiveness to secure the 
reimbursement and formulary inclusion of new medicinal products.1 Economic evaluations, conducted 
as part of a broader health technology assessment (HTA), are often the preferred approach to 
demonstrate value; that is, whether the benefits of a new treatment are sufficient to justify any 
additional cost. There is a trend of increasing requirements for cost-effectiveness to secure 
reimbursement, including in the United States.2 As pricing and market access has become increasingly 
contingent on the ability to demonstrate cost-effectiveness, there has emerged the potential for the 
pharmaceutical industry to benefit from methods of quantifying the economic potential of drug 
candidates earlier in development.  
Earlier value assessments are especially pertinent in the context of the high and increasing cost of 
drug development that is skewed toward the later phases. The return on investment in 
pharmaceutical R&D has also steadily declined since 2010,3 although returns would not appear to have 
yet fallen below those for other large companies.4 The mean cost of phase 3 development has been 
estimated to exceed the cost of phase 2 by more than a factor of four.5 It is, therefore, desirable to 
fail development candidates at the earliest stage possible before incurring large costs – hence the 
mantra “fail fast, fail cheap”. While it does appear that there has been some success in shifting project 
terminations towards earlier phases in recent decades, the proportion failing at phase 3 remains high.6  
Studies of attrition rates show inadequate efficacy at phase 3 to be the primary reason for termination 
but that 22% failed for commercial reasons7 and 24% for strategic reasons.8 Even if marketing 
authorisation is granted there may be difficulty securing reimbursement. In the UK, for example, in a 
sample of drug appraisals only around half of funding decisions were positive without restrictions.9 
Considerations of the requirements for drug reimbursement ought to be integrated within the drug 
development decision-making process. Failure to do so may risk late stage termination of projects that 




medicines gaining regulatory approval only to prove unmarketable at a commercially viable price or 
failing to gain substantive market share. 
Early economic evaluation during drug development aims to increase R&D efficiency through earlier 
termination of commercially non-viable drugs and, inform pricing strategies by predicting the price 
reimbursement authorities would be willing to pay.10 Economic evaluation should ideally be applied 
iteratively, beginning in the pre-clinical phase and subsequently updated as clinical data emerges11,12 
and used beyond go/no-go and pricing decisions, to also inform strategic, data collection and risk 
management decisions.11 However, the methods and data sources required to parameterise early 
economic models have not been well described, including how to address the issue that outcomes in 
terms of the safety and efficacy of treatments will either be unknown or highly uncertain. 
It has been proposed that safety and efficacy inputs to early economic models may be obtained using 
pharmacometric models, by extrapolating from early phase data along with the associated 
uncertainty.13 In this approach, pharmacometric models, developed routinely in the early clinical 
phases of drug development, are used to simulate the potential range in outcomes from proposed 
pivotal clinical trials14 which in turn serve as inputs to a pharmacoeconomic model. As pharmacometric 
models provide a mathematical description of the exposure-response relationships, whilst also 
accounting for inter-individual variability, inputs to pharmacoeconomic models could be simulated for 
specific patient subgroups, doses, regimens, or drug adherence scenarios. It also provides a framework 
that allows uncertainty in safety and efficacy to be captured and propagated through to the economic 
endpoints, which is essential in order to quantify decision uncertainty and the value of conducting 
further research.15 
In this article we refer to this methodology as linked pharmacometric-pharmacoeconomic (PMPE) 
modelling and simulation. Our aim in this study was to review the published literature for applications 
of linked PMPE modelling and simulations since the original publications in this area; to identify 




making; to describe the key challenges in implementing the methods in practice, and; consider what 





3. Types of Early Economic Evaluation in Drug Development  
The concept of early economic evaluation, which may be defined as ‘all methods used to inform 
industry and other stakeholders about the potential value of new medical products in development, 
including methods to quantify and manage uncertainty’,16 first appeared in the literature in the early 
the nineties.10 Published applications of early economic evaluation in drug development are 
limited16,17 and appear to be less numerous than those for medical device development.18 Review 
articles of early economic evaluation have presented various means of classifying or categorising the 
types of early economic evaluation that are possible, in terms of their methodology and the types of 
research question which they address.19,20 
Linked PMPE modelling is one approach available to enable and enhance early economic evaluation 
in drug development. We consider three broad categories of drug development problems to which 
linked PMPE could be applied: i) applications where the primary focus is on ‘go/no-go’ decisions; ii) 
applications whose primary focus is to inform study design and development strategy; and iii) 
applications used primarily to inform decisions relating to pricing, reimbursement or market access 
(PRMA) strategies (Table 1). A fourth category is presented for completeness, to include those 
published PMPE studies that are not focussed on drug development questions but may be used to 




4. Economic Evaluation of Pharmaceuticals 
Health technology assessment (HTA) is a multidisciplinary process that uses explicit methods to 
determine the value of a health technology at different points in its lifecycle. The purpose is to inform 
decision-making in order to promote an equitable, efficient, and high-quality health system.21 This 
often includes economic evaluation, defined as the process of conducting an analysis of alternative 
courses of action in terms of both their costs and consequences, taking the perspective of society, a 
health care provider or payer.22 This process is inherently comparative and is commonly applied when 
a medicine has received marketing authorisation, to inform the decision of whether, and to what 
extent, it will replace the existing standard of care (SoC). An important source of evidence providing 
inputs to such evaluations, in particular relating to efficacy, are the pivotal phase 3 clinical trials.23 
However, other sources of evidence may also be required and pharmacoeconomic modelling involves 
methods for linking surrogate and clinical endpoints, evidence synthesis, generalising trial findings, 
extrapolation to appropriate time horizons and quantifying decision uncertainty. This is represented 
by ‘late stage HTA’ in Figure 1, whereby costs and outcomes of two treatments, ℞1 and ℞2, are 
informed from pivotal clinical trial(s) and provide inputs to an economic evaluation. 
An important outcome measure in the context of HTA is the quality-adjusted life year (QALY), 
developed in order to facilitate comparisons across different disease areas and interventions. QALYs 
are based on utilities, which are preference-based valuations of health-related quality of life, and 
measured on a scale where perfect health = 1 and death = 0.24 QALYs are calculated as the integral of 
utility scores over time, often over a patient’s lifetime. Aggregated QALYs therefore represent an 
overall measure of length of life weighted by quality of life.25 Weights are intended to represent 
societal preferences for being in a given health state and are obtained via survey methods. The 
evidence for the utilities associated with different states of health, for use in HTA, is often collected 
within pivotal clinical trials but may also be taken from external sources and applied to observed 




cost is known as the incremental cost-effectiveness ratio (ICER). Some reimbursement authorities 
make decisions by relating ICERs to threshold values of willingness to pay, above which health 





5. Linked Pharmacometric-Pharmacoeconomic Case Studies 
We conducted a literature research to identify studies that had used linked pharmacometric and 
pharmacoeconomic models in order to address questions relating to drug development or the use of 
existing medicines. We searched PubMed, Medline, EconLit, Embase and BIOSYS Previews for articles 
published between January 2001 and April 2020. Search terms included: ‘pharmacometric’, 
‘pharmacokinetic pharmacodynamic’, ‘drug development’ and ‘investigational compound’. These 
terms were searched in combination with the terms ‘cost-effectiveness’, ‘pharmacoeconomic, ‘health 
economics’ and ‘economic evaluation’. The relevant articles that this search identified were used to 
identify additional relevant studies by examining study references. We also used the results of 
previous reviews on early economic evaluation in medical product development.16,17  
We identified ten publications implementing linked PMPE models since the first publication by Hughes 
et al., outlining the methodology in 2001.13 Following the study by Poland & Wada,26 there was a 
considerable delay until the subsequent studies began to emerge, the first being Pink et al.27 in 2012. 
There may, however, have been applications of linked PMPE performed within the pharmaceutical 
industry that have not been published. The following subsections summarise each of the published 
studies in turn, grouped according to the type of analysis as outlined in Table 1. The important 
characteristics of each study including the disease area, the perspective adopted, the approximate 
timing within, or beyond, drug development to which the approach would be most applicable, the 
type of decision addressed and specific research questions, are summarised in Table 2. A summary of 
the types of sub-models the studies included, model structures and specific analyses performed is 
provided in Table 3. 
5.1. Drug Development Applications 




The economic viability of a project should be assessed at every stage of drug development as new 
data becomes available. This includes decisions ranging from whether to initiate a drug discovery 
effort to whether to continue into phase 3 clinical trials. Economic evaluations performed at very early 
stages, during drug discovery or in pre-clinical phases, could help identify target product profiles most 
likely to achieve the types and scale of benefits that would be required to obtain a price in a range 
that may justify further R&D investment. Subsequently, as biomarker or early outcome data from 
clinical studies emerge, pharmacometric models can be used to extrapolate early results to late stage 
pharmacoeconomic outcomes to assess whether efficacy and safety thresholds are likely to have been 
met and justify continued development. 
An early stage economic evaluation using linked PMPE was conducted by Hill-McManus et al. to assess 
the potential for new xanthine oxidase inhibitors to achieve price premiums relative to the existing 
treatment options.28 The pharmacology of the comparator, another xanthine oxidase inhibitor, was 
described using a compartmental pharmacokinetic (PK) model and multicompartment semi-
mechanistic pharmacodynamic (PD) model. This was linked to a pharmacoeconomic model which 
predicted rates of clinical events and extrapolated to a longer-term time horizon to estimate 
incremental costs and QALYs. Hypothetical compounds were simulated by modifying the clearance 
and potency parameters of the existing comparator, to estimate the value-based price of such drugs 
under conditions of “real world” drug adherence. Simulations predicted a distribution of possible 
hypothetical drug prices that would meet a cost-effectiveness threshold of £20,000 per QALY. The 
results showed only modest price premiums would be acceptable even for much more potent, or 
slowly cleared (more forgiving29) hypothetical drugs; suggesting that discovery and development of 
such compounds is unlikely to be commercially viable unless therapeutic benefit in addition to 
reduction in gout flares could be identified. 
Slejko et al. reported a PD model-based meta-analysis (MBMA) linked to a pharmacoeconomic model 




(COPD).30  The purpose of the analysis was to predict the threshold of drug efficacy that would be cost-
effective. The MBMA was used to predict (as non-linear functions) the COPD exacerbation rates given 
changes in FEV1 with placebo or drug treatment, which then served as inputs to a Markov 
microsimulation pharmacoeconomic model estimating costs and QALYs over a 1-year period. The 
results indicated that a hypothetical anti-inflammatory drug that increased FEV1 by 50ml, decreased 
exacerbations by 26%, and if priced at €35 per month, would be associated with an ICER ranging from 
€13,000 to €207,000 per QALY gained across different patient subgroups, with the lowest ICER in 
patients with severe COPD. The simulations identified which COPD drug profiles are most likely to be 
cost-effective and in which patient population this is most likely to be achieved. 
Early estimates of cost-effectiveness, or of pricing options, may be useful in planning for product 
launch and approaches to market access. A linked PMPE model of rituximab for the treatment of 
follicular lymphoma, undertaken as a proof of concept, was used to predict the trial-based cost-
effectiveness of a trial that had yet to report.27 Using a population PK model and a PD model which 
linked serum drug concentrations to progression-free survival, the analysis simulated a phase III 
randomized controlled trial comparing rituximab, fludarabine and cyclophosphamide to rituximab, 
cyclophosphamide, vincristine and prednisolone induction chemotherapies for the treatment of stage 
II–IV follicular lymphoma. Utility and cost estimates for Markov model states representing disease 
progression, no progression, or death were used to project lifetime estimates of QALYs and health 
service costs. Two further analyses of rituximab as first line and maintenance therapy were compared 
with economic models based on completed trial results used by the National Institute for Health and 
Care Excellence (NICE). The predicted ICERs in these analyses were found to differ by 25% or less. 
5.1.2. Research and development (R&D) strategy and trial design  
Applications that are used to inform R&D strategy or trial design cover a wide range of possible 
decisions. Examples could include portfolio decisions or compound selection, choice of target patient 




be studied by examining the impact of imperfect drug adherence (or interventions to improve 
adherence), the choice of comparator or the inclusion/exclusion criteria. It may also be possible to 
determine optimal sample sizes of clinical trials with respect to the value provided by reduced 
uncertainty in expected value-based prices, e.g. Brennan & Breeze (2014)31 and Dranitsaris et al. 
(2012)32, but there are no published examples of this being done using pharmacometric models. 
Another potential application is to inform decisions regarding clinical trial data collection, beyond 
sample size, according to the resulting reduced cost of the uncertainty in inputs to economic models, 
i.e. value of information.15 
Poland & Wada (2001)26 presented a real-world prospective case study of an HIV protease inhibitor 
drug in late-stage development. The objective was to evaluate alternative development strategies that 
differed in terms of the doses and regimens for treatment naïve or experienced patients. Models of 
patient adherence, PK, PD and viral dynamics were linked to an economic model in order to compare 
the development strategies in terms of their predicted net present value (NPV). The results highlighted 
the importance of adherence if using once-a-day dosing and suggested there would be high value to 
a longer lasting – more forgiving – drug formulation.33 Many details of the modelling were omitted 
from the publication in order that the drug and pharmaceutical company involved could not be 
identified. 
Van Hasselt et al. developed a PMPE model to assess the toxicity, dose intensity, disease progression, 
and cost-effectiveness of eribulin for castration-resistant prostate cancer.34  The analysis utilized a 
semi-physiological model for neutropenia, the major dose-limiting toxicity of eribulin, a disease 
progression/clinical outcome model relating prostate-specific antigen dynamics to overall survival, 
and an economic model that incorporated quality of life and treatment-related costs. The motivation 
for the analysis was to illustrate how trial design and decision-making in oncology could be further 




alternative treatment regimens, disease progression criteria, dose reduction rules, patient population 
and comparators were performed, and QALYs and ICERs were presented for a range of scenarios. 
Hill-McManus & Hughes demonstrated how linked PMPE modelling could be used to optimise phase 
3 trial design, focussing primarily on sample size determination.35 This case study adopted a Bayesian 
decision theoretic approach to trial design in which the optimal design is that which is predicted to 
result in the greatest expected utility. The utility function employed was the expected pharmaceutical 
company return on investment. A prior distribution for the efficacy of a new treatment was obtained 
via pharmacometric based clinical trial simulation and used to calculate a posterior distribution given 
a proposed sample size. Posterior treatment efficacy was converted to a value-based drug price 
distribution via a pharmacoeconomic model and subsequently to company return on investment. This 
enabled uncertainty to be propagated from aspects of drug pharmacology through to the predicted 
return on investment, where drug prices are contingent on the results of phase 3 testing. Such an 
approach may have value in supporting trial design decisions and in identifying costly sources of 
uncertainty, and thus inform future research and development strategies. 
5.1.3. Pricing, reimbursement and market access decisions 
Linked PMPE modelling may be able to inform pricing decisions such as price setting to ensure 
sufficiently high likelihood of reimbursement, or to assess differences in potential prices across 
different markets and inform market entry strategies. A case study of urate-lowering therapies for 
treating gout showed how, prior to proceeding into phase 3 testing, a probability distribution of drug 
prices could be simulated based on target cost-effectiveness thresholds.36 The simulations used 
uncertainty in PKPD model parameters to estimate the likelihood of cost-effectiveness over a range 
of drug prices and tested alternative biomarker to clinical outcomes modelling approaches and 
adherence scenarios. The results highlighted the importance of adherence in clinical trials for these 




5.2. Other Applications 
Linked PMPE modelling has been applied to research questions beyond drug development, adopting 
a societal, regulatory or payer perspective. This can enable reimbursement authorities or regulators 
to assess cost-effectiveness of treatments, or treatment strategies, where there is an absence of direct 
trial evidence. Published case studies using linked PMPE have been applied to assess the cost-
effectiveness of pharmacogenetic-guided warfarin dosing algorithms,37 to compare influenza 
pandemic treatment scenarios in terms of cost-effectiveness38 and to make early predictions of the 
potential cost-effectiveness of generic versions of the direct oral anticoagulant dabigatran.39 
Pink et al. used pharmacometric-based prediction of time within international normalized ratio (INR) 
range for warfarin based on a genetic dosing algorithm, to estimate the cost-effectiveness of different 
oral anticoagulation treatment strategies in patients with non-valvular atrial fibrillation.37 Justification 
for taking this approach was based on there being many possible dosing algorithms – far more than 
might be conceivably tested in a clinical trial; and the magnitude of the differences in both benefits 
and costs being small, requiring a prohibitively expensive trial to demonstrate differences in 
haemorrhagic or stroke outcomes. The authors used a pharmacometric model that described the 
effects of CYP2C9 and VKORC1 genetic polymorphisms, alongside other clinical parameters, on the 
relationship between warfarin dose and INR response. Linked to this, the economic model utilized 
evidence from an indirect comparison of treatment options, a meta-analysis of the association 
between time in INR range and risk of haemorrhagic events and strokes, and costs and utilities derived 
from published sources. The principal finding, of an ICER for genotype-guided warfarin versus clinical 
algorithm–dosed warfarin of £13,226 per QALY gained compared favourably with a later analysis using 
trial data.40 This example provided further evidence of the feasibility of applying a linked PMPE 
approach to estimate cost-effectiveness. 
Kamal et al. developed an integrated modelling framework, including pharmacometric, epidemiology 




practical to conduct clinical trials.38 This utilized a PKPD model linked to a compartmental 
epidemiological susceptible, exposed, infected, recovered model, and economic model of costs and 
health outcomes. The number of infected patients per population of susceptible individuals was 
simulated for a series of pandemic scenarios, varying oseltamivir dose, basic reproductive number, 
and drug uptake. The study assumed the perspective of a potential US payer and used QALYs as the 
measure of benefit and assessed cost-effectiveness using ICERs. The results indicated that across all 
pandemic scenarios, 75 mg twice-daily oseltamivir was cost-saving and more effective compared to 
no treatment, with QALY gains of 430 per 100,000 population over 1 year in a scenario of low 
transmissibility and low severity. The authors concluded that this approach has the potential to inform 
government planning for an effective and cost-effective response to influenza pandemics. We 
consider that there is broad scope for linked PMPE in the assessment of value of antimicrobials, where 
this value depends on a drug’s properties as well as where it is positioned in the strategic use of 
antimicrobials.41 
Wang et al. applied linked PMPE modelling and simulation to assess the effectiveness and cost-
effectiveness of potential future generic versions of the direct oral anticoagulant (DOAC) dabigatran.39 
DOACs have a narrow therapeutic range, and there is concern that future generics at the outer limits 
of bioequivalence may not be equivalent in terms of clinical effectiveness and might not be cost-
effective versus the branded drug despite the difference in price. The authors used a previously 
published PKPD model and adapted and reproduced a previously published economic model. The 
models were used to simulate clinical event rates and to predict QALYs and ICERs for hypothetical 
generic dabigatran at the typical limits of bioequivalence of 80% and 125% systemic exposure, as well 
as at the more conservative bioequivalence limits of 90% to 112.5%. The results showed that generics 
with 80% systemic exposure relative to the branded medication were predicted to result in higher 
QALYs and lower costs, whereas those with 125% systemic exposure showed worse cost-effectiveness 
due to increase in bleeding events. The authors acknowledge that these simulations represent the 




effectiveness prediction may be useful in assessing the value of generic substitution particularly where 






6. Considerations in Linking Pharmacometrics and Pharmacoeconomics 
In this section we consider five important concepts in the application of linked PMPE models during 
drug development and how they have been dealt with in the published case studies. These concepts 
are i) value outcomes, typically these have been based on QALYs, but this may not always be 
appropriate; ii) evidence on comparators, which is an essential input for linked PMPE models; iii) the 
approach to linking multiple intermediate endpoints; iv) dealing with model uncertainty, and; v) the 
challenge of model validation. 
6.1. Value Outcomes 
All but one of the case studies identified used the QALY as the outcome measure for use in a cost-
effectiveness calculation. There may, however, be other treatment effects, beyond those captured in 
QALYs, which may contribute to how patients or society value new treatments and their opportunity 
costs.42,43 These could include convenience (e.g. dose frequency, method/route of administration or 
treatment monitoring), as well as measures that incorporate patient preferences and/or risk aversity 
over the distribution of outcomes, and broader societal considerations (e.g. equity or work 
productivity). Where reimbursement decisions are known to be based on a range of different criteria, 
the task of early economic evaluation is likely to be more challenging.  
In theory such additional dimensions of treatment effect could be incorporated within early economic 
evaluations if the necessary studies are performed at an earlier point in development. Methods such 
as discrete choice experiments44 are available for assessing the relative weights that patients, or 
payers, place on different treatment outcomes. The results could then be represented by willingness-
to-pay for product characteristics or translated into health state utility increments for use in cost-
effectiveness analysis.45 Alternatively, reimbursement decision making involving a range of criteria can 
be modelled using multi-criteria decision analysis (MCDA).46 Regardless of the approach adopted, an 




6.2. Evidence on Comparators 
Pharmacoeconomic evaluations are inherently comparative; in HTA this will typically involve assessing 
the incremental benefit and cost of a new treatment relative to another that is often the current 
standard of care (SoC). The relevant comparators are those that the reimbursement authority 
considers would be most widely used in the clinical context, and it is essential that these are identified. 
Whilst from a drug development perspective, the only data available on a development candidate may 
be that which is generated ‘in-house’ through the conduct of clinical studies, evidence on comparators 
could come from a wide range of sources. Incorporating evidence on comparators in PMPE models 
may be achieved using point estimates from previous studies, published PKPD models or meta-analytic 
approaches for evidence synthesis. 
A variety of approaches have been used to incorporate comparator evidence in the published 
examples of linked PMPE. Van Hasselt (2015)34, Hill-McManus (2019)28, Kamal et al. (2017)38 and Wang 
et al. (2020)39 effectively focussed on a single drug and so additional evidence on active comparators 
was not required. Poland and Wada (2001)26 did not conduct a comparative economic evaluation and, 
therefore, did not explicitly consider the likely outcomes of comparators. Hill-McManus et al. (2018)36 
and Hill-McManus & Hughes (2020)35 used published PK models for the comparators and constructed 
a PD model based on published phase 1 trial data and other published models but did not use a meta-
analytic framework. Pink et al. (2012)27 used trial results for comparators as well as data from an 
existing meta-analysis of clinical trials. Both Pink et al. (2014)37 and Slejko et al. (2016)30 employed 
meta-analyses that linked an intermediate biomarker endpoint to clinical endpoints. This latter 
example used an MBMA and could, therefore, predict economic outcomes for a range of drug 
efficacies as well as trial design inputs. 
Meta-analyses of published data have become the main sources of evidence on comparative 
effectiveness and safety.47 Traditional meta-analysis focuses on head-to-head comparisons of drugs 




involving these drugs. Network meta-analysis (NMA) combines direct and indirect evidence, allows 
comparisons of multiple treatments48, and thereby synthesises a greater share of the available 
evidence than a traditional meta-analysis.49 NMA is often used in HTA for simultaneous indirect 
comparison of effects of multiple treatments using studied doses and treatment durations50, and 
therefore, has limited potential to extrapolate to different doses and durations.  
MBMA is a meta-analysis that incorporates parametric pharmacology models for the effect of 
treatment and patient population characteristics (e.g. different baseline disease severity) on 
outcomes.51 In a drug development setting, MBMA models are useful to predict different doses, time 
points, patient populations, and endpoints when progressing from one phase of development to the 
next. MBMA may inform i) quantitative criteria for the target product profile to position a new drug 
relative to the SoC and/or emerging competitors, ii) probability of success (e.g. being preferred over 
SoC and/or emerging competitors), iii) early insights into best-in-class potential and iv) probability of 
technical success in demonstrating superiority or non-inferiority in an actual head-to-head trial. 
Additional examples of strategic integration of MBMA across the drug research-development–
utilization continuum are provided by Upreti & Venkatakrishnan (2019)51. More recently, a framework 
for dose‐response and time-course model‐based network meta‐analysis (MBNMA) has been proposed 
that combines, often nonlinear, MBMA modelling with the statistically robust properties of NMA.52,53  
6.3. Handling of Multiple Endpoints 
Within the context of drug development, the purpose of PMPE modelling is to provide a framework 
wherein patient relevant outcomes forming the basis for reimbursement decisions (e.g. survival and 
quality of life) can be estimated from drug exposure. However, a direct relationship between drug 
exposure and such outcomes is unlikely to be characterised during drug development, especially in 
early phases. Efficacy and safety are instead measured using intermediate endpoints, often 
biomarkers, which may change during drug development as the scale and nature of clinical testing 




reimbursement authorities (e.g. leukemia54) as the basis for decisions making and, therefore, used as 
primary surrogate endpoints in pivotal phase 3 clinical trials.55 The nature and validity of surrogate 
endpoints, and whether surrogates are accepted by regulators/reimbursement authorities, may 
influence how, and whether, PMPE modelling is informative.  
The use of biomarker and clinical endpoints in published PMPE studies is summarised in Table 4, using 
definitions taken from the Biomarkers Definition Working Group study.56 A diagrammatic 
representation of the linking of intermediate and final endpoints in three of the published case studies 
in given in Figure 2. Two studies did not use biomarker endpoints at all, and drug exposure was linked 
directly to the rates of clinical events. These studies were either assessing the use of a drug in a new 
indication27 or as a generic version of an already marketed drug. Therefore, these benefitted from the 
availability of numerous clinical studies having been reported, including pivotal phase 3 trials. 
Most PMPE case studies used a biomarker as an intermediate endpoint that was then linked to clinical 
event rates. Typically, the relationship between biomarker and clinical events was well evidenced and 
had been used previously for other therapies in the same, or similar, indication. For example, Pink et 
al. (2014)37 performed a meta-analysis of the relationship between INR and bleeding and 
thromboembolic events; and, Slejko et al. (2016)30 used MBMA to combine data across many studies 
to describe the relationship between FEV1 and COPD exacerbations. Two case studies in gout used a 
biomarker, serum uric acid, whose relationship to the relevant clinical event rates is poorly 
evidenced.28,36 This biomarker, however, although not validated,57 was used as a surrogate outcome 
in the clinical trials. The linking of these endpoints was thus undertaken as part of the 
pharmacoeconomic component of the modelling. 
6.4. Modelling Uncertainty 
Methods to quantify the extent of uncertainty in modelled outcomes and to examine the relative 
contribution of model inputs to that uncertainty are used in both pharmacometrics58 and 




relating to the model parameters (usually due to sampling) or to model structural assumptions. That 
similar approaches to handling these types of uncertainty have emerged in both disciplines suggests 
these may be readily applied to linked PMPE models. To examine parameter uncertainty, 
pharmacometrics and pharmacoeconomics both use similar methods of Monte Carlo simulation for 
sensitivity analyses in which models are evaluated multiple times with parameters varied 
simultaneously over the entire parameter space. In pharmacometrics this is known as global sensitivity 
analysis (GSA)60, while in pharmacoeconomics, it is known as probabilistic sensitivity analysis (PSA).61 
Approaches to assessing structural uncertainty include transforming to parametric uncertainty62,63 and 
model averaging.64,65 
The published PMPE case studies considered model uncertainty using a variety of one-way (or local) 
sensitivity analyses and probabilistic (or global) sensitivity analyses. The studies using a probabilistic 
sensitivity analysis approach generated a distribution of outcomes by assigning probability 
distributions to model inputs and using Monte Carlo simulation to generate model outputs using new 
sets of input parameters.27,28,30,36,37 Where the influence of specific parameters was assessed this was 
only undertaken using one-way (or local) sensitivity analyses, not using methods that account for 
model outputs being non-linear in input parameters. More useful for R&D decisions and study design 
is likely to be the relative contribution of the uncertainty in specific model parameters to the overall 
uncertainty in modelled outcomes. There are methods from both pharmacometrics/systems 
pharmacology and pharmacoeconomics for this purpose,60 for example, pharmacoeconomic models 
have applied methods taken from Bayesian decision theory.66 One of the case studies did adopt a 
value of information approach35 but stopped short of computing the expected value of partial perfect 
information for model parameters. None of the studies attempted to examine the impact of structural 
uncertainty beyond some one-way sensitivity analyses testing alternative modelling assumptions.  




By model validation we are referring to the process of evaluating whether a model is a proper and 
sufficient representation of the system it is intended to represent in view of an application. This 
encompasses whether the model is in accordance with what is known about the system and the extent 
that the results can serve as a solid basis for decision making.67 Validation is an important element in 
model development and is relevant to a number of different aspects, such as the conceptual model, 
the selection and processing of input data and the outputs of the operational model.68 Other terms 
are also used to describe this process, such as model qualification in the disciplines of 
pharmacometrics and quantitative systems pharmacology.69,70 Linked PMPE models may be more 
difficult to validate owing to the additional uncertainty introduced as compared with application of 
the individual components.30 The common technique of comparison of model outcomes with external 
data is often problematic for pharmacoeconomic models where such empirical data may only become 
available years in the future, if at all.  
Few of the published linked PMPE case studies have included significant reporting of efforts to validate 
the models. Here we summarise efforts described to validate model outcomes by comparing these to 
empirical data. Pink et al. (2012)27 compared simulated ICERs with two actual trial-based economic 
evaluations, and observed differences of 18% and 25%, although the 95% central ranges of predicted 
ICERs also included the trial-based results. The authors predicted the cost-effectiveness for a 
comparison between treatments based on a trial that had yet to begin (NCT01303887), which will 
provide a valuable opportunity to assess model validity when this trial reports. Pink et al. (2014)37 
performed external validation of the PKPD model by comparing simulated versus actual time in 
therapeutic range. These authors also showed comparable ICERs when using simulated and trial-based 
biomarker response data,40 based on incremental QALY gains (warfarin genotyping vs standard dosing) 
of 0.003 and 0.004, and costs of £41 and £26 from each study, respectively. Slejko et al. (2016)30 
conducted external validation of a MBMA using published trial results. Hill-McManus et al. (2018)36 
obtained ICERs of between £39,000 to £78,000 per QALY gained, depending on assumed drug 





Linked PMPE modelling and simulation has been recognised as a methodology that can enable and 
enhance economic evaluation during drug development and beyond. There is a small but growing 
literature of applications to drug development decisions problems and to those regarding optimisation 
of existing therapies. We identified ten examples from the published literature which are summarised 
in this paper. These span a wide range of drugs and disease areas; with applications concerning drug 
go/no-go; R&D strategy and trial design; and PRMA decisions. Other identified applications include 
estimating the cost-effectiveness of complex pharmaceutical interventions (such as in the context of 
pharmacogenomics), generic medicines with narrow therapeutic indices, and treatments of infectious 
diseases. 
During early drug development, compared to conventional pharmacoeconomic evaluations, linked 
PMPE may potentially enable a far broader range of research questions to be addressed by exploiting 
pharmacometric models of the exposure response relationships. As the published case studies show, 
this can include consideration of the economic outcomes associated with treatment of specific patient 
subgroups, alternative doses or regiments, or protocol deviations such as non-adherence. The 
overarching objective is that incorporating such approaches within the decision-making process will 
contribute to reducing drug development costs by improving decisions regarding project termination 
and trial design. However, linked PMPE may be of no greater value to decision makers than existing 
approaches where there is limited patient data, lack of evidence on comparators or poorly 
characterised relationships between biomarkers and clinical outcomes. 
It would seem that there is currently a great deal of interest in early economic evaluation and the 
coming years are likely to see a growth in the number of applications, furthering our understanding of 
the potential of such innovative interdisciplinary methods. The recent article by Grutters et al.18 and 
the subsequent commentaries72 provides a valuable discussion from multiple perspectives on some 




economic modelling in general. An article published whilst ours was under review, aimed towards a 
health economics audience, also discusses the literature on incorporating pharmacometrics into 
pharmacoeconomics.73 These authors conclusions, in line with our own, point to the potential of this 
methodology to inform drug development decision-making and the need for greater collaboration 
between the pharmacoeconomics and pharmacometrics communities. 
Nearly all the case studies adopted incremental QALYs as the measure of treatment benefit, which 
yields an ICER as a metric of cost-effectiveness when combined with incremental costs. The application 
of early economic evaluation will be more complicated in situations where QALYs do not capture all 
the important treatment benefits, and when payers do not apply ICER-based decision rules or their 
process and criteria for decision making is not transparent. This may necessitate the use of additional 
techniques such as MCDA and other measures of treatment value. Early engagement with payers is 
clearly important in order that emerging therapies can be assessed against appropriate criteria, and 
so that future studies are designed to generate evidence that satisfies the requirements of decision 
makers.  
The linked PMPE modelling framework provides a tool to combine and propagate the uncertainty from 
inputs to an estimate of uncertainty in economic outcomes, such as cost-effectiveness or drug price. 
We found that most of the published case studies had performed a probabilistic assessment of 
outcome uncertainty in which input parameters were varied simultaneously over the entire parameter 
space. The linked PMPE methodology, in which a series of models link across multiple intermediate 
endpoints, will typically require a large number of input parameters that may be highly uncertain early 
in drug development. This would then result in highly uncertain economic outcomes with limited value 
to decision makers. In this case, value of information analysis74 may be more useful than the point 
estimates, enabling the cost associated with sources of uncertainty to be identified and valuing study 
designs according to the extent that they reduce uncertainty.15 Only one of the case studies used a 




resulting evidence in terms of its influence on drug prices.35 This framework could be readily extended 
to assess the influence of parameters on decision uncertainty (expected value of partial perfect 
information66) and to direct future research efforts. These methods are well established in healthcare 
resource allocation decisions from a societal perspective, but there are few examples published taking 
a pharmaceutical industry perspective.31,75 We consider that value of information may have 
considerable potential to add value during drug development and would benefit from further 
research.15 
Each of the published case studies has the form of a standalone exercise designed to inform a drug 
development decision or optimise the use of existing therapies. Early economic models, however, 
could be applied iteratively throughout drug development, incorporating emerging data on treatment 
efficacy, safety and pharmacology to provide increasingly robust assessments of the commercial 
potential of development candidates. This approach has long since been encouraged11,12 but, as far as 
we are aware, economic modelling during drug development is not routinely applied in this way. The 
pharmacoeconomic model for a specific disease area, target population and type of treatment may, 
structurally, not change substantially over the drug development timeline. Safety and efficacy profiles, 
providing inputs to pharmacoeconomic models, will be estimated with increasing confidence as 
further studies are conducted and pharmacometric models may then enable applications to a wider 
range of research questions. This could involve an iterative process of Bayesian updating of model 
inputs, synthesising evidence across the development timeline, such as has been demonstrated for 
medical device development.76 
The concept of a framework in which quantitative methods are applied iteratively to inform decision 
making during drug development is an established principle of the model informed drug development 
(MIDD) paradigm.77 MIDD embraces the integration of systems pharmacology and pharmacometric 
modelling approaches; empirical time course analysis including disease progression modelling, 




methods in dose/trial optimisation, to inform labelling and R&D decision-making is well established.77–
79 There is a growing appreciation of the value of these methods in enabling more efficient 
development and regulatory acceptance of novel medicines.80,81 It is also increasingly being accepted 
by regulators that MIDD offers an alternative approach to risk-benefit evaluation where there is high 
unmet medical need and/or there are difficulties in conducting trials.80–83 Incorporating early 
pharmacoeconomic modelling within the MIDD framework would naturally promote linkage between 
these methods and associated disciplines.84 
This review was limited by only having access to applications of linked PMPE modelling and simulation 
that were published. This may, in fact, only be a small proportion of all such analyses that have taken 
place, since the majority may be being performed by the pharmaceutical industry in-house and 
deemed unpublishable due being considered too commercially sensitive. Nevertheless, the published 
literature contains a small number of examples that demonstrate the range of therapies, disease areas 
and decisions for which insights can be gained through the use this interdisciplinary approach. 
A potential barrier to the integration of pharmacoeconomic modelling within drug development 
decision making is the historical separation of clinical development and commercial functions within 
the pharmaceutical industry, with technical experts and modellers in separate organisational arms 
linked only by high-level review and governance. It has been suggested that substantial changes to 
the pharmaceutical industry operating model, including the breaking down of functional silos, are 
needed to help reverse the trend of declining R&D productivity.3,85 Our view is that optimal 
functioning, with respect to effective integration of predictive modelling within a defined 
organisational structure, needs to be driven by common and integrated goals that promote cross-
functional collaborative end to end working. With this in mind the R&D business process, starting with 
the desired target product profile, needs to foster greater cross-functional and interdisciplinary 
alignment to enable innovative interdisciplinary activities such as linked PMPE modelling and 




Relevant to both the early engagement with payers to understand what constitutes value and to the 
bridging of company clinical development and commercial functions are initiatives to foster dialogue 
between regulators, payer/HTA/reimbursement organisations and the pharmaceutical industry. 
These include the US FDA paired meeting pilot program for providing regulatory input on MIDD 
issues80 and the availability of parallel scientific advice from both the EMA and HTA bodies86. These 
may naturally encourage cross-functional collaboration and provide information regarding the payer 
landscape which is essential to early pharmacoeconomic modelling. Early pharmacoeconomics is also 
relevant to the risk minimization and management efforts and could promote the development of 
commercial risk management plans. Furthermore, it has been proposed that risk minimization may be 
operationalised in a way that serves as a bridge between clinical drug development and commercial 
functions within organisations.87 
Other barriers to the application of linked PMPE modelling and simulation include technical issues 
such as the appropriate software platforms, and the challenge of communicating novel 
interdisciplinary methods to decision makers. Widespread application of this methodology may 
benefit from a common data science platform for managing data and associated expertise. The use of 
certain software packages within each discipline may also restrict integration, such as the prevailing 
use of NONMEM (pharmacometrics) and MS Excel (pharmacoeconomics). The use of more flexible 
(and open source) solutions such as R, Python or Julia is becoming more widespread and this would 
support a collaboration between disciplines. The disciplines also differ to some extent in the standard 
terminology used to describe the same, or similar, modelling issues, presenting a potential source of 
confusion. Finally, decision makers across R&D and commercial functions may require education in 
relation to the potential productivity gains to be achieved through novel or interdisciplinary 





In conclusion, while linked PMPE modelling and simulation remains relatively novel, with few 
published case studies, it has potential across a range of applications from early drug development to 
post-marketing. It has advantages over conventional pharmacometric studies that do not assess the 
future value of compounds beyond market authorization; and conversely, it has advantages over 
standard pharmacoeconomic practices which do not utilise exposure response relationships. Closer 
integration and collaboration between the disciplines of clinical pharmacology, pharmacometrics and 
health economics, is needed in order to realise the potential benefits and promote greater acceptance 
of this methodology. 
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TABLE REFERENCES 
1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred 











Combine payer value criteria, disease area knowledge and comparator data to 
inform decision of whether to initiate drug discovery  
Early development 
Update economic models as clinical data becomes available and model potential 
pricing options and market size to inform decision to continue development 
Late development 
Simulation of phase 3 trial to predict pricing options or cost-effectiveness to inform 
decision to progress into phase 3 testing 
R&D strategy and 
trial design  
Any 
Prediction of cost-effectiveness or pricing for a range of scenarios to inform 
selection of indication, target product profile, dose or dosing regimen 
Quantify the impact of uncertainty in economic model inputs to inform the data 
collection objectives of later studies 
PRMA All stages 
Prediction of benefit and cost-effectiveness over comparators under different 
scenarios to enhance value proposition  






Predict the cost-effectiveness of interventions where trials would be 
difficult/impossible (e.g. choose among many treatment strategies) 
Table 1. Classification and purpose of linked PMPE applications* 






Study Disease area Drug(s) Perspective1 
Approximate 
timing1 
Type of decision1 Research questions 







and trial design 
Dose selection 
Dose regimen selection 
Adherence monitoring 













Pink et al. (2014) NVAF Warfarin 
Applicable to 
multiple perspectives 
Post-marketing Optimise treatments 
Cost-effectiveness of 
pharmacogenetic dosing 










R&D strategy and 
trial design 
Early cost-effectiveness 







and trial design 
Cost-effectiveness by subgroup 






Dose selection by pandemic 
scenario 










Impact of non-adherence on cost 
effectiveness 




Drug discovery Go/no-go 
Value of more potent/extended 
half-life ULT 








Cost-effectiveness of generic 
dabigatran 







and trial design 
Optimise trial design to maximise 
company return on investment 
Table 2. Summary of applications of PMPE in terms of disease area and type approach and decision problem* 


















Poland & Wada (2001) Yes Yes Company profit model Yes Yes No 
Pink et al. (2012) Yes No Markov model No No Yes 
Pink et al. (2014) Yes No DES Yes No Yes 
Van Hasselt et al. (2015) Yes Yes IPS No Yes Yes 
Slejko et al. (2016) No Yes Individual Markov No No Yes 
Kamal et al. (2017) Yes Yes Decision tree No No No 
Hill-McManus et al. (2018) Yes Yes Markov model Yes No No 
Hill-McManus et al. (2019) Yes Yes Markov model Yes No No 
Wang et al. (2020) Yes No Markov model No No No 
Hill-McManus & Hughes (2020) Yes Yes Markov model Yes Yes No 
Table 3. The types of sub-models and specific analyses employed in available examples of PMPE studies 















Poland & Wada (2001) HIV viral load NA NA NPV NPV 
Elicitation 
One-way 




Costs & QALYs ICER PSA 




Strokes & major 
bleeds 
Costs & QALYs ICER PSA 
Van Hasselt et al. (2015) Prostate-specific antigen No 
Quality of life & 
survival 
Costs & QALYs ICER One-way SA 
Slejko et al. (2016) 
Forced expiratory volume 
1 second 
NA COPD exacerbations Costs & QALYs ICERs PSA 
Kamal et al. (2017) 
Time to 
cessation of viral shedding 
No 
Influenza-related 
complication & death 
Costs & QALYs ICERs One-way SA 
Hill-McManus et al. (2018) 
Serum uric acid 
concentration (biomarker) 
Yes Acute gout flares Costs & QALYs ICERs 
PSA (PKPD 
model) 
Hill-McManus et al. (2019) 
Serum uric acid 
concentration (biomarker) 
Yes Acute gout flares Costs & QALYs Drug price 
PSA (PKPD 
model) 
Wang et al. (2020) NA No 
Strokes & major 
bleeds 
Costs & QALYs ICERs PSA 
Hill-McManus & Hughes (2020) 
Serum uric acid 
concentration (biomarker) 
Yes Acute gout flares Costs & QALYs Drug price/ROI 
PSA (PKPD 
model) 
Table 4. The types of endpoints used at stages in available examples of PMPE studies* 
QALY: quality adjusted life year; ICER: incremental cost-effectiveness ratio; PSA: probabilistic sensitivity analysis; SA: sensitivity analysis; PKPD: 
pharmacokinetic-pharmacodynamic; NPV: Net present value; ROI: Return on investment. 
* Biomarker: a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention; surrogate: a biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is 
expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence; 
















Figure 1. Use of evidence sources within pharmacoeconomic evaluations for late-stage health technology assessment, and early stage linked PMPE 
modelling where costs and outcomes of one or more drugs are informed via pharmacometric modelling and simulation. 
℞: treatment; SoC: standard of care; ICER: incremental cost-effectiveness ratio; PK: pharmacometrics; PD: pharmacodynamics; RWE: real-world evidence; 
MBMA: model-based meta-analysis; QSP: quantitative systems pharmacology 
 
Figure 2. Examples of the simplified endpoint modelling sequences or causal pathways implemented in published PMPE case studies 
PK: pharmacokinetics; PD: pharmacodynamics; C: drug plasma concentration; sUA: serum uric acid concentration; PFS: progression free survival; PSA: 
prostate specific antigen; QALY: quality adjusted life year; ICER: incremental cost-effectiveness ratio. 
